Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Shares Outstanding (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Shares Outstanding for 8 consecutive years, with $47.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 91.02% to $47.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.1 million through Dec 2025, up 91.02% year-over-year, with the annual reading at $47.1 million for FY2025, 91.02% up from the prior year.
  • Shares Outstanding for Q4 2025 was $47.1 million at Whitehawk Therapeutics, roughly flat from $47.1 million in the prior quarter.
  • The five-year high for Shares Outstanding was $47.1 million in Q4 2025, with the low at $734000.0 in Q1 2021.
  • Average Shares Outstanding over 5 years is $26.0 million, with a median of $24.5 million recorded in 2023.
  • Peak annual rise in Shares Outstanding hit 99900.0% in 2021, while the deepest fall reached 98.19% in 2021.
  • Over 5 years, Shares Outstanding stood at $20.9 million in 2021, then increased by 16.94% to $24.4 million in 2022, then grew by 0.49% to $24.6 million in 2023, then grew by 0.52% to $24.7 million in 2024, then skyrocketed by 91.02% to $47.1 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $47.1 million, $47.1 million, and $47.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.